Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764705 | 0.92 | NSD2 (0.40) | NSD2EGLN1TTKKDM1A | |
| SCHEMBL15717759 | 0.90 | KDM1A (0.38) | NSD2EGLN1TTKKDM1A | |
| SCHEMBL17309064 | 0.88 | KCNH2 (0.44) | CNR1CNR2 | |
| SCHEMBL15717195 | 0.82 | NSD2 (0.41) | NSD2EGLN1TTKKDM1A | |
| SCHEMBL17309052 | 0.82 | PIK3CD (0.37) | EGLN1EGLN2LTB4R2 | |
| SCHEMBL17309063 | 0.81 | OXTR (0.39) | EGLN1MAPKAPK2KDM1AEGLN2LTB4R2 | |
| SCHEMBL15717984 | 0.78 | KCNH2 (0.44) | — | |
| SCHEMBL15717794 | 0.74 | RET (0.40) | NSD2KDM1AEGLN2 | |
| SCHEMBL17309068 | 0.73 | CACNA1H (0.33) | NSD2EGLN1 | |
| SCHEMBL15718117 | 0.72 | KDM1A (0.40) | EGLN1KDM1AEGLN2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | NSD2 4247/4885EGLN1 2927/4885MAPKAPK2 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.